EGFR and non-small cell lung carcinoma: Specifically, the identification of activating mutations in the epidermal growth factor receptor (EGFR) gene (present in approximately 15% of Caucasian patients) introduced the era of targeted therapy in advanced NSCLC, shifting treatment from platinum-based chemotherapy to tyrosine kinase inhibitors (TKIs) to manage first-line advanced disease [3].